Shared on07 May 25Fair value Decreased 6.05%
AnalystLowTarget has increased revenue growth from -1.1% to 0.7%.
Patent Expirations And Biosimilar Pressures Will Diminish Value
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 12 Analysts
Published
21 Apr 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$295.00
6.1% overvalued intrinsic discount16 Aug
US$313.13
1Y
-2.4%7D
3.9%